Inotersen

Phase 3

Ionis Pharmaceuticals, Inc. (IONS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in FAP

View Full Landscape

Drug Information

Target Indication

FAP

Clinical Trial

NCT01737398

Last updated: 12/4/2025

Patent & Exclusivity

ActiveRLD

Latest Patent Expiry

Apr 29, 2031(4y 8m)

Patents Listed

Application

NDA 211172

Source: FDA Orange Book

Regulatory Approvals

EMA7/6/2018

Tegsedi

Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

OrphanAccelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

IONS

Ionis Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ION363Phase 3

Amyotrophic Lateral Sclerosis

VolanesorsenPhase 3

Familial Chylomicronemia Syndrome

OlezarsenPhase 3

Familial Chylomicronemia Syndrome

ION582Phase 3

Angelman Syndrome

zilganersenPhase 3

Alexander Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts